Histopathology of Hepatic Sinusoidal Obstruction Syndrome After Neoadjuvant Oxaliplatin-Based Chemotherapy

1. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology. 2009; 49:1729–1764.10.1002/hep.22772Search in Google Scholar

2. Rubbia-Brandt L. Sinusoidal Obstruction Syndrome. Clin Liver Dis. 2010; 14:651–668.10.1016/j.cld.2010.07.009Open DOISearch in Google Scholar

3. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22:27–42.10.1055/s-2002-23204Search in Google Scholar

4. Valla D-C, Cazals-Hatem D. Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol. 2016; 40:378-385.10.1016/j.clinre.2016.01.006Open DOISearch in Google Scholar

5. Lin G, Wang JY, Li N, Li M, Gao H, Ji Y, Zhang F, et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol. 2011; 54:666-67.2114689410.1016/j.jhep.2010.07.031Search in Google Scholar

6. Adam R. Colorectal cancer with synchronous liver metastases. Br J Surg. 2007; 94:129–131.10.1002/bjs.5764Search in Google Scholar

7. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup Trial 40983): a randomized controlled trial. Lancet. 2008;371:1007–1016.10.1016/S0140-6736(08)60455-9Search in Google Scholar

8. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict longterm survival. Ann Surg. 2004; 240:644–657.10.1097/01.sla.0000141198.92114.f6135646615383792Search in Google Scholar

9. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET) Ann Surg. 2004; 240:438–447.Search in Google Scholar

10. Rubbia Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–466.10.1093/annonc/mdh09514998849Search in Google Scholar

11. Fernandez FG, Ritter JJ, Goodwin W, Linehan DC, Hawkins WG, Strasberg SM. Effect of Steatohepatitis Associated with Irinotecan or Oxaliplatin Pretreatment on Resectability of Hepatic Colorectal Metastases. J Am Coll Surg 2005; 200: 845-853.10.1016/j.jamcollsurg.2005.01.02415922194Search in Google Scholar

12. Milićević M, Bulajić P, Žuvela M, Dervenis C, Basarić D, Galun D. A Radiofrequency-Assisted Minimal Blood Loss Liver Parenchyma Dissection Technique. Dig Surg 2007; 24:306–313.10.1159/00010366317657157Search in Google Scholar

13. Rubbia-Brandt L, Lauwers G Y, Wang H, Majno P E, Tanabe K, Zhu A X, et al. Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 2010; 56:430–439.10.1111/j.1365-2559.2010.03511.x20459550Open DOISearch in Google Scholar

14. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol. 2006; 24:4983-90.10.1200/JCO.2006.05.815617075116Open DOISearch in Google Scholar

15. Vreuls CP, Van Den Broek MA, Winstanley A, Koek GH, Wisse E, Dejong CH, Olde Damink SW, Bosman FT, Driessen A. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology. 2012; 61:314-8.10.1111/j.1365-2559.2012.04208.x22571348Search in Google Scholar

16. Rubbia-Brandt L, Mentha G, Terris B. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. J Am Coll Surg. 2006; 202:199-200.10.1016/j.jamcollsurg.2005.09.01016377516Search in Google Scholar

17. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006; 24:2065–2072.10.1200/JCO.2005.05.307416648507Open DOISearch in Google Scholar

18. Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives- a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015; 50:781-9.10.1038/bmt.2015.52445678825798682Search in Google Scholar

19. Rubbia-Brandt L, Tauzin S, Brezault C, Delucinge-Vivier C, Descombes P, Dousset B, et al. Gene expression profiling provides insights into pathways of oxaliplatinrelated sinusoidal obstruction syndrome in humans. Mol Cancer Ther 2011; 10:687—96.10.1158/1535-7163.MCT-10-107221330458Search in Google Scholar

20. Agostini J, Benoist S, Seman M, Julie C, Imbeaud S,Letourneur F, et al. Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. J Hepatol 2012; 56:869-76.10.1016/j.jhep.2011.10.02322200551Open DOISearch in Google Scholar

21. Marzano C, Cazals-Hatem D, Rautou PE, Valla DC. The significance of nonobstructive sinusoidal dilatation of the liver: impaired portal perfusion or inflammatory reaction syndrome. Hepatology 2015; 62.3: 956-963.10.1002/hep.2774725684451Search in Google Scholar

22. Wang X, Qi X, Guo X. Tusanqi-related sinusoidal obstruction syndrome in china. A systematic review of the literatures. Medicine. 2015; 94:e942.10.1097/MD.0000000000000942461646226061322Search in Google Scholar

23. Tarantino G, Scalera A, Finelli C. Liver-spleen axis: intersection between immunity, infections and metabolism. World J Gastroenterol. 2013; 19:3534–3542.10.3748/wjg.v19.i23.3534369103223801854Open DOISearch in Google Scholar

24. Imai K, Emi Y, Iyama KI, et al. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol. 2014; 40:559–566.10.1016/j.ejso.2013.12.00924388740Open DOISearch in Google Scholar

25. Soubrane O, Brouquet A, Zalinski S, Terris B, Brézault C, Mallet V, Goldwasser F, Scatton O. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Ann Surg. 2010; 251:454-60.10.1097/SLA.0b013e3181c7940320160638Search in Google Scholar